

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

## Intravaginal Progesterone

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

**\*Louisiana Medicaid – See State Specific Mandates**

Medications	Quantity Limit
Crinone Progesterone Suppositories Progesterone Powder	May be subject to quantity limit

### **APPROVAL CRITERIA**

Requests for daily vaginal progesterone for prevention of preterm birth may be approved if the following criteria are met:

- I. Therapy is initiated between 16 and 24 weeks of gestation; **AND**
- II. Individual has a singleton pregnancy and one of the following:
  - A. A prior history of a preterm singleton delivery before 37 weeks gestation; **OR**
  - B. Individual has a short cervix (measuring by ultrasound to be less than 20 mm).

Requests for daily vaginal progesterone for prevention of preterm birth may **not** be approved for the following:

- I. Individual has other factors for preterm delivery in the current pregnancy, including, but not limited to the following:
  - A. Multiple gestations pregnancy; **OR**
  - B. Cervical cerclage; **OR**
  - C. A uterine anomaly; **OR**
  - D. Positive tests for cervicovaginal fetal fibronectin; **OR**
  - E. Preterm labor.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
Louisiana		Provision of injectable or vaginal progesterone for every eligible pregnant woman with a history of pre-term labor or a short cervix found in the current pregnancy. The MCO shall not require prior authorization of progesterone for the prevention of premature birth unless written approval from the Medicaid Medical Director is obtained. The MCO will provide progesterone access to eligible members in a timely fashion.

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 14, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. American College of Obstetricians and Gynecologists (ACOG) Committee Practice Bulletin No. 130. Prediction and prevention of preterm birth. Obstet Gynecol. 2012; 120(4):964-973.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.